Table of Contents

• Overview of Clinical Research
• Target Conditions and Patient Population
• Trial Design and Methodology
• Treatment Administration and Combination Therapy
• Safety Assessment and Primary Outcomes
• Current Trial Status and Enrollment

Overview of Clinical Research

Clinical trials are currently investigating 1-{4-[2-(5-Ethoxymethyl-2-Methyl-Phenylamino)-Oxazol-5-Yl]-Phenyl}-Imidazolidin-2-One, an investigational drug also known by its research designation AB8939^[1]. This compound is being studied as a potential treatment option for patients with certain types of blood cancers who have not responded to standard treatments or whose disease has returned after previous therapy.

The research program for 1-{4-[2-(5-Ethoxymethyl-2-Methyl-Phenylamino)-Oxazol-5-Yl]-Phenyl}-Imidazolidin-2-One represents an early-stage clinical investigation aimed at understanding how this drug behaves in the human body and whether it can provide therapeutic benefit to patients with difficult-to-treat blood cancers^[1]. The study is designed to gather critical information about safety, dosing, and initial effectiveness that will guide future research decisions.

Target Conditions and Patient Population

The clinical trial investigating 1-{4-[2-(5-Ethoxymethyl-2-Methyl-Phenylamino)-Oxazol-5-Yl]-Phenyl}-Imidazolidin-2-One focuses on patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS)^[1]. These are serious blood and bone marrow disorders that affect how the body produces blood cells.

Acute myeloid leukemia is a type of cancer that starts in the bone marrow, the soft inner part of bones where blood cells are made. In AML, the bone marrow produces abnormal white blood cells that grow quickly and crowd out healthy blood cells. This can lead to serious complications including infections, bleeding, and fatigue.

The trial specifically targets patients whose disease is classified as relapsed or refractory^[1]. This means the study is designed for patients in challenging situations:

• Relapsed disease: Patients whose cancer has returned after a period of improvement or remission following previous treatment
• Refractory disease: Patients whose cancer has not responded to standard treatments or has stopped responding to therapies that previously worked

These patient populations represent significant unmet medical needs, as relapsed and refractory AML and MDS are particularly difficult to treat and often have limited effective treatment options available^[1].

Trial Design and Methodology

The study investigating 1-{4-[2-(5-Ethoxymethyl-2-Methyl-Phenylamino)-Oxazol-5-Yl]-Phenyl}-Imidazolidin-2-One is designed as a Phase 1/2 clinical trial^[1]. This combined phase approach allows researchers to address multiple important questions within a single study framework.

The Phase 1 component of the trial focuses on fundamental safety questions^[1]. During this portion, researchers aim to:

• Identify dose-limiting toxicities, which are side effects severe enough to prevent further dose increases
• Determine the maximum tolerated dose (MTD), the highest amount of the drug that can be given safely without causing unacceptable side effects
• Establish the recommended dose for future expanded testing
• Understand the pharmacokinetics of the drug, meaning how it is absorbed, distributed, metabolized, and eliminated from the body

The Phase 2 component builds upon the safety information gathered in Phase 1 and begins to evaluate the drug’s efficacy, or how well it works in treating the target condition^[1]. This portion of the study uses the dosing information established in Phase 1 to assess whether 1-{4-[2-(5-Ethoxymethyl-2-Methyl-Phenylamino)-Oxazol-5-Yl]-Phenyl}-Imidazolidin-2-One provides meaningful clinical benefit to patients.

The trial is classified as an interventional study, meaning that researchers actively assign patients to receive specific treatments rather than simply observing their care^[1]. The study plans to enroll approximately 60 patients total across both phases^[1].

Treatment Administration and Combination Therapy

In the clinical trial, 1-{4-[2-(5-Ethoxymethyl-2-Methyl-Phenylamino)-Oxazol-5-Yl]-Phenyl}-Imidazolidin-2-One (AB8939) is administered as a daily intravenous injection^[1]. This means the drug is delivered directly into the bloodstream through a vein, typically through a needle or catheter. The daily dosing schedule allows for consistent drug exposure over time.

The trial protocol includes the possibility of combination therapy, where 1-{4-[2-(5-Ethoxymethyl-2-Methyl-Phenylamino)-Oxazol-5-Yl]-Phenyl}-Imidazolidin-2-One may be used together with other established medications for treating blood cancers^[1]. The study interventions include:

• AB8939 (1-{4-[2-(5-Ethoxymethyl-2-Methyl-Phenylamino)-Oxazol-5-Yl]-Phenyl}-Imidazolidin-2-One): The investigational drug being tested, given as an intravenous injection
• Vidaza (azacitidine): An approved medication for treating myelodysplastic syndromes and AML, available as a powder for suspension that can be given intravenously or subcutaneously (under the skin)
• Venclyxto (venetoclax): An approved oral medication (film-coated tablets) used in combination therapies for AML

The inclusion of these combination options allows researchers to evaluate whether 1-{4-[2-(5-Ethoxymethyl-2-Methyl-Phenylamino)-Oxazol-5-Yl]-Phenyl}-Imidazolidin-2-One works effectively when used alone or in combination with other therapies^[1]. This approach is common in cancer research, as combination treatments often provide better outcomes than single-drug approaches.

Safety Assessment and Primary Outcomes

The primary outcome measure for the clinical trial investigating 1-{4-[2-(5-Ethoxymethyl-2-Methyl-Phenylamino)-Oxazol-5-Yl]-Phenyl}-Imidazolidin-2-One is the rate of dose-limiting toxicity (DLT)^[1]. This measurement is critical for understanding the safety profile of the drug and determining appropriate dosing for future studies.

Dose-limiting toxicities are specific adverse events or side effects that are considered severe enough to prevent further increases in the drug dose. By carefully monitoring and documenting these toxicities, researchers can identify the threshold at which the drug’s risks begin to outweigh its potential benefits. This information is essential for establishing safe dosing guidelines.

The study’s primary objectives focus on defining the safety and tolerability of 1-{4-[2-(5-Ethoxymethyl-2-Methyl-Phenylamino)-Oxazol-5-Yl]-Phenyl}-Imidazolidin-2-One in patients with refractory or relapsed AML and MDS^[1]. To achieve this, researchers will:

• Systematically identify and document all dose-limiting toxicities that occur during the study
• Determine the maximum tolerated dose, which represents the highest dose that can be administered without causing unacceptable side effects in the majority of patients
• Establish the recommended dose for dose expansion trials, which will be used in subsequent larger studies to further evaluate the drug’s effectiveness

These safety assessments form the foundation for all future clinical development of 1-{4-[2-(5-Ethoxymethyl-2-Methyl-Phenylamino)-Oxazol-5-Yl]-Phenyl}-Imidazolidin-2-One^[1]. Without establishing a clear safety profile and appropriate dosing range, the drug cannot progress to larger efficacy studies or eventual regulatory approval.

Current Trial Status and Enrollment

The Phase 1/2 clinical trial investigating 1-{4-[2-(5-Ethoxymethyl-2-Methyl-Phenylamino)-Oxazol-5-Yl]-Phenyl}-Imidazolidin-2-One is currently listed with a status of Suspended^[1]. This designation indicates that the trial has been temporarily paused and is not actively enrolling new patients or administering treatment to participants at this time.

When a clinical trial is suspended, it means that recruitment and treatment activities have been halted, but the study has not been permanently terminated. Trials may be suspended for various reasons, and the suspension may be temporary while specific issues are addressed. During a suspension period, ongoing safety monitoring and data analysis may continue, but no new patients can join the study and current participants typically do not receive further doses of the investigational treatment.

The trial was designed with a planned enrollment of approximately 60 patients^[1]. This enrollment target represents the total number of participants the study aims to include across both the Phase 1 dose-escalation portion and the Phase 2 expansion cohort. The relatively modest enrollment number is typical for early-phase clinical trials, which focus on generating detailed safety and preliminary efficacy data rather than definitive proof of effectiveness.

The trial is registered with the identifier 2024-516641-39-00, which allows patients, healthcare providers, and researchers to track the study and access official information about its design, objectives, and current status^[1].